HOOKIPA CMO Schlienger resigns; Board member Dr. Peters named interim clinical lead

HOOKIPA Pharma Inc.

CMO Dr. Katia Schlienger resigns effective September 30, 2023 to pursue new opportunities.
Board member Dr. Malte Peters, former MorphoSys R&D head, appointed Senior Clinical Advisor ad interim.
CEO reaffirms focus on HB-200 randomized trial, HB-300 prostate program, and Roche/Gilead collaborations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.